Bio

David Martin serves as the Managing Director and Head of Equity Research of Bloom Burton. By seeking out and researching publicly traded healthcare and emerging biotechnology companies, he identifies opportunities that are differentiated and undervalued, thereby providing for Bloom Burton’s clients, investment ideas with the potential for substantial returns. David also serves on the Board of Directors of The NanoMedicines Innovation Network (NMIN). Before joining Bloom Burton, David most recently served as Vice President, Corporate Development and Investor Relations at a high growth medical device company. Earlier in his career, he led the Healthcare Equity Research team at one of Canada’s largest independent investment dealers, and he has also worked in the clinical diagnostics industry. David received a Ph.D. Biochemistry from the University of Western Ontario for oncology research which he conducted at the London Regional Cancer Centre and at the Princess Margaret Hospital. He also holds a MBA degree from the Richard Ivey School of Business.